奥美沙坦
奥美沙坦 性质
| 熔点 | 186-188°C |
|---|---|
| 沸点 | 738.3±70.0 °C(Predicted) |
| 密度 | 1.33 |
| 储存条件 | 2-8°C |
| 溶解度 | 可溶于DMSO（轻微）、甲醇（轻微、加热） |
| 酸度系数(pKa) | 2.39±0.50(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| 稳定性 | 吸湿性 |
| InChIKey | VTRAEEWXHOVJFV-UHFFFAOYSA-N |
| SMILES | C1(CCC)N(CC2=CC=C(C3=CC=CC=C3C3=NNN=N3)C=C2)C(C(O)=O)=C(C(O)(C)C)N=1 |
| CAS 数据库 | 144689-24-7(CAS DataBase Reference) |
奥美沙坦 用途与合成方法
奥美沙坦的商品名：Benicar (美国)、Olmetec (欧洲)，是一款血管紧张素II受体拮抗剂药物，用于治疗高血压症。
通过阻断血管紧张素1型受体（AT1），奥美沙坦抑制肾素-血管紧张素系统，防止因循环中的血管紧张素II诱发血管收缩与体积膨胀，具强有力的抗高血压活性。 Olmesartan (RNH-6270) 是血管紧张素II受体 (AT1R) 拮抗剂，常用于高血压的相关研究。Olmesartan (0.7-5 mM; 24, 48 and 72 h) inhibits the growth of HeLa cells as a concentration- and time-dependent mode.
Cell Viability Assay
| Cell Line: | Human cervical cancer cell line (HeLa) |
| Concentration: | 0.7- 5 mM |
| Incubation Time: | 24, 48 and 72 h |
| Result: | IC 50 s against HeLa cell line are 4.685 and 1.651 mM for 48 and 72 h, respectively. |
Repeated dosing of olmesartan (1 mg/kg, 2 mg/kg, p.o.) dose-dependently decreases mean arterial blood pressure (MAP) in SHR without significant influence on body weight and food intake during 10 weeks. Olmesartan (5 mg/kg/d, p.o.) and Hyd treatments lower systolic blood pressure to the same degree in mice. Olmesartan treatment inhibits cardiac hypertrophy, evaluated by echocardiography, heart weight, cross-sectional area of cardiomyocytes, and gene expression. Olmesartan treatment reverses decreased gene expressions of ACE2 and Mas receptor of Ren-Tg mice and inhibits enhanced NADPH oxidase (Nox)4 expression and reactive oxygen species.
安全信息
| WGK Germany | WGK 3 |
|---|---|
| RTECS号 | NI4014100 |
| 海关编码 | 29339900 |
| 存储类别 | 11 - 可燃固体 |
| 毒害物质数据 | 144689-24-7(Hazardous Substances Data) |
奥美沙坦 化学药品说明书
奥美沙坦 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-10-20 | XW0114468924703 | 奥美沙坦 | 144689-24-7 | 500mg | 940 |
| 2026-10-20 | XW0114468924701 | 奥美沙坦 | 144689-24-7 | 100mg | 260 |
